Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00837811) looked at a medicine called LY2127399 in people with rheumatoid arthritis. It was an extension study, meaning participants had already taken part in one of two earlier related trials. A total of 182 people were enrolled across three groups, which differed by the dose they received: 60 people received a steady 60 mg dose, 121 people received a dose that varied between 60 mg and 120 mg, and 1 person was in a third dosing group. The trial's primary focus was on tracking unwanted medical events (called adverse events) and serious adverse events that occurred while participants were taking the study drug, as well as any unusual results from blood and urine tests. The reported data shows that, among those who experienced any unwanted medical event during treatment, 38 out of 60 participants were recorded in the 60 mg group, and 95 out of 121 in the 60/120 mg group. Serious adverse events were reported in 4 participants in the 60 mg group and 16 in the 60/120 mg group. Abnormal laboratory results reported as adverse events were very rare — only 1 participant in the 60/120 mg group during treatment, and 1 in the same group during the follow-up period. The reported data also shows changes in several secondary measures across groups. For the number of tender joints (out of 28 checked), the average change from the starting point was −9.2 joints in the 60 mg group and −6.5 joints in the 60/120 mg group. For swollen joints, the reported average change was −7.6 in the 60 mg group and −5.3 in the 60/120 mg group. On a 0–100 scale where participants rated their own arthritis activity, the average reported change was −26.1 mm in the 60 mg group and −16.7 mm in the 60/120 mg group. Physicians' ratings on the same type of scale showed average changes of −29.1 mm and −18.4 mm respectively. Results for the third dosing group (one participant only) are included in the submitted data but are not meaningful to describe given the very small number involved. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25168268) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have signed and given written consent to take part in the study.
- Women must not be pregnant, breastfeeding, or likely to become pregnant during the study.
- You must have previously taken part in one of two specific earlier studies (called NCT00689728 or NCT00785928).
Who may not be able to join:
- During one of the two earlier studies, you experienced a serious safety concern — such as a serious infection, a severe reaction to the study drug, or any bad reaction that caused you to stop treatment — that the study doctor believes makes it too risky for you to continue.
- During one of the two earlier studies, you received a medication that was not allowed by the study rules, including certain unapproved drugs, specific medications used to treat conditions like arthritis (confirm with trial site), or live vaccines.
- You are currently enrolled in another clinical trial that involves an experimental drug or device, or you are taking part in any other type of medical research study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UCT/GMT-5 hours, EST), Eli Lilly and Company
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs); Number of Participants With Planned Laboratory Evaluations (Including Hematology, Clinical Chemistry, and Urinalysis) Reported as AEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.